In the present study, we investigated the promoter methylation status of MAGE-A1 and -A3, which were the most frequent targets for immunotherapy, in gastric cancers, and analysed the correlation between the MAGE-A1 and -A3 methylation status and clinicopathological parameters of gastric cancer patients, including event-free survival. This evidence concerns the gene MAGEA1 and gastric cancer.